Celldex Therapeutics

- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 160
- Market Cap
- $2.5B
- Website
- http://www.celldex.com
Avalo Therapeutics Appoints Rita Jain to Board as AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa Progresses
Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.
Celldex Advances Barzolvolimab Phase 3 Program in Chronic Urticaria with Strong Pipeline Progress
Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.
Chronic Spontaneous Urticaria Market Expected to Reach $36 Billion by 2035 as Novel Targeted Therapies Transform Treatment Landscape
The global chronic spontaneous urticaria (CSU) market is projected to grow from $15.1 million in 2024 to $36 billion by 2035, driven by rising diagnosis rates and innovative biologic therapies.
ACTG Launches ACACIA Trial in Africa to Evaluate HIV Cure Strategy
The ACTG has initiated the ACACIA (A5417) study, a Phase 2 trial, to assess the safety and efficacy of broadly neutralizing antibodies (bNAbs) in HIV treatment.
Celldex Therapeutics Initiates Phase 2 Trial of Barzolvolimab for Atopic Dermatitis
Celldex Therapeutics has begun a Phase 2 clinical trial to evaluate barzolvolimab for treating moderate to severe atopic dermatitis, a chronic inflammatory skin condition.
Urticaria Clinical Trial Pipeline Heats Up with Novel Therapies in Development
The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.
Evommune Secures $115 Million to Advance Clinical Trials for Chronic Immune Conditions
Evommune has raised $115 million in Series C funding to support Phase 2 trials for EVO756 and EVO301, targeting chronic immune conditions like urticaria and atopic dermatitis.
Barzolvolimab Shows Promise in Phase II Trial for Chronic Inducible Urticaria
Barzolvolimab significantly improved outcomes in patients with cold urticaria and symptomatic dermographism compared to placebo, as shown in a phase II trial.
Barzolvolimab Achieves Primary and Secondary Endpoints in Chronic Inducible Urticaria Phase 2 Trial
Celldex Therapeutics' barzolvolimab demonstrates clinical benefit in chronic inducible urticaria (CIndU) patients in a randomized, placebo-controlled study.
Barzolvolimab Achieves Primary and Secondary Endpoints in Phase 2 CIndU Trial
Celldex's barzolvolimab demonstrated significant clinical benefit in patients with chronic inducible urticaria (CIndU) in a randomized, placebo-controlled Phase 2 study.